Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 1997

View Archived Issues

Lilly continues to develop compounds for postmenopausal syndrome

Endothelin antagonists from SmithKline Beecham

Wyeth-Ayerst describes antiinflammatory agents

MS&D prepares antimigraine pyrrolo-pyridine derivatives

Centocor describes peptide inhibitors of selectin binding

Novel antitumor agents from Universidad Complutense

Positive preliminary clinical results for Atragen in leukemia and Kaposi's sarcoma

Selective CB2 receptor agonists prepared by Merck Frosst

Major gene associated with glioblastoma multiforme discovered

New device for carpal tunnel syndrome

Hokuriku discloses agents for urinary incontinence

Vasopressin antagonists from JT

IDE sought for new technique for glaucoma surgery

New HPV DNA test introduced in Europe

Procept's PRO-2000 covered by U.S. patent

Cationized AVP fragment for learning and memory disorders from Yakult

Guilford's neuroimmunophilin ligands covered by U.S. patent

FDA tentatively approves generic acyclovir

Stavudine delays HIV progression in zidovudine-experienced patients

VIMRx licenses factor IXa inhibitor from Columbia University

Transdermal nicotine associated with clinical improvement in ulcerative colitis

IntraBiotics/Synt:em to develop protegrin analogues

Abgenix acquires rights to antibody for transplant rejection

First Estrophasic OC introduced in the U.S.

New low-dose OC cleared by FDA

Dusa reports data on Levulan as CIN therapy

New epilepsy option approved in the U.S.

Preliminary data reported from Alkermes' RMP-7/carboplatin phase II trial

Pharmadigm's PB-OO5 enters phase II as burn treatment

Amylin acquires rights to cardiovascular agents from Hoechst Marion Roussel